Inhalon Biopharma announced that it has contracted with hVIVO to conduct a Phase 2a challenge study of nebulized IN-002, an antibody against RSV, now that Inhalon has completed IND-enabling studies. The company said that it expects to initiate the trial of IN-002 in 2026. Inhalon’s pipeline of inhaled antibodies also includes IN-003 against metapneumovirus, IN-005 against influenza, and IN-006 and IN-007 against SARS-CoV-2.
Inhalon President and CEO John Whelan commented, “There are currently no approved treatments for the underlying RSV infection. Inhalon’s inhaled antibody treatment approach not only targets the underlying pathophysiology of RSV and other respiratory infections, but also provides painless self-administration by patients in their own homes, potentially reducing hospitalizations.”
In a separate press release, hVIVO CEO Yamin “Mo” Khan said, “We previously identified the next generation of vaccines and antivirals, including mucosal-based delivery systems, as being a key growth driver for our challenge trial business. . . . Inhalon’s IN-002 and its innovative delivery platform could provide a novel way to combat RSV infections. The study is also notable for including three dosing arms, further supporting the trend of biopharma companies looking to obtain greater actionable insights into their candidates earlier to help inform later-stage field trials.”
Read the Inhalon Biopharma press release
Read the hVIVO press release
